Exome Sequencing Provides Diagnostic Assay for Intellectual Disability
|
By LabMedica International staff writers Posted on 22 Nov 2012 |
A molecular based diagnostic assay has been used determine whether one or more genetic mutations explain a patient's intellectual disability.
Exome sequencing, which deciphers over 21,000 protein-coding genes and not the entire human genome, can be used as a diagnostic assay to determine the genetic mutations that may elucidate why some patients suffer from significant limitations both in intellectual functioning and in adaptive behavior.
A team of scientists at Radboud University (Nijmegen, The Netherlands) performed exome sequencing of 100 patients with unexplained cognitive impairment, and uncovered 79 genes with unique de novo mutations. These de novo mutations were present in the DNA of the patients but not in that of their parents whose exomes also were sequenced.
The diagnostic interpretation revealed that 16 of the 100 mutations were causative, or pathogenic. Ten of these mutations occurred in genes already known to be involved in intellectual disability, and three X-linked maternally inherited mutations were identified. In addition, de novo mutations were uncovered in three novel candidate genes, which after follow-up were found to be more frequently mutated in patients with intellectual disability. Furthermore, disruptive de novo mutations were identified in 19 additional genes with a functional link to intellectual disability. Because 19 genes were found in only a single patient, a conclusive diagnosis based on these findings could not be made.
Joseph de Ligt, MSc, bioinformatician and PhD student in human genetics, said, “The child with a cognitive disability is often an isolated case without family history of the condition, and that intellectual disability occurs in about 1% of the population. All de novo as well as X-linked mutations identified in this study were interpreted in the context of the clinical diagnosis.” The results of this study were presented on November 8, 2012, at the American Society of Human Genetics meeting, held in San Francisco, (CA, USA).
Related Links:
Radboud University
Exome sequencing, which deciphers over 21,000 protein-coding genes and not the entire human genome, can be used as a diagnostic assay to determine the genetic mutations that may elucidate why some patients suffer from significant limitations both in intellectual functioning and in adaptive behavior.
A team of scientists at Radboud University (Nijmegen, The Netherlands) performed exome sequencing of 100 patients with unexplained cognitive impairment, and uncovered 79 genes with unique de novo mutations. These de novo mutations were present in the DNA of the patients but not in that of their parents whose exomes also were sequenced.
The diagnostic interpretation revealed that 16 of the 100 mutations were causative, or pathogenic. Ten of these mutations occurred in genes already known to be involved in intellectual disability, and three X-linked maternally inherited mutations were identified. In addition, de novo mutations were uncovered in three novel candidate genes, which after follow-up were found to be more frequently mutated in patients with intellectual disability. Furthermore, disruptive de novo mutations were identified in 19 additional genes with a functional link to intellectual disability. Because 19 genes were found in only a single patient, a conclusive diagnosis based on these findings could not be made.
Joseph de Ligt, MSc, bioinformatician and PhD student in human genetics, said, “The child with a cognitive disability is often an isolated case without family history of the condition, and that intellectual disability occurs in about 1% of the population. All de novo as well as X-linked mutations identified in this study were interpreted in the context of the clinical diagnosis.” The results of this study were presented on November 8, 2012, at the American Society of Human Genetics meeting, held in San Francisco, (CA, USA).
Related Links:
Radboud University
Latest Molecular Diagnostics News
- Blood Test Could Spot Common Post-Surgery Condition Early
- New Blood Test Can Help Predict Testicular Cancer Recurrence
- New Test Detects Alzheimer’s by Analyzing Altered Protein Shapes in Blood
- New Diagnostic Markers for Multiple Sclerosis Discovered in Cerebrospinal Fluid
- Cell-Free DNA Predicts Bloodstream Infections in Children with Leukemia
- Study Uses Blood Samples to Identify Diseases Years Before They Start
- MicroRNA-Based Method Predicts CKD and Cardiovascular Risk
- Swab Test Helps Transplant Patients Receive Right Anti-Rejection Medication Dose
- Blood Test Predicts Which Bladder Cancer Patients May Safely Skip Surgery
- Ultra-Sensitive DNA Test Identifies Relapse Risk in Aggressive Leukemia
- Blood Test Could Help Detect Gallbladder Cancer Earlier
- New Blood Test Score Detects Hidden Alcohol-Related Liver Disease
- New Blood Test Predicts Who Will Most Likely Live Longer
- Genetic Test Predicts Radiation Therapy Risk for Prostate Cancer Patients
- Genetic Test Aids Early Detection and Improved Treatment for Cancers
- New Genome Sequencing Technique Measures Epstein-Barr Virus in Blood
Channels
Clinical Chemistry
view channelNew Blood Test Index Offers Earlier Detection of Liver Scarring
Metabolic fatty liver disease is highly prevalent and often silent, yet it can progress to fibrosis, cirrhosis, and liver failure. Current first-line blood test scores frequently return indeterminate results,... Read more
Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
Ovarian cancer is often diagnosed at a late stage because its symptoms are vague and resemble those of more common conditions. Unlike breast cancer, there is currently no reliable screening method, and... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read moreMicrobiology
view channel
Rapid Sequencing Could Transform Tuberculosis Care
Tuberculosis remains the world’s leading cause of death from a single infectious agent, responsible for more than one million deaths each year. Diagnosing and monitoring the disease can be slow because... Read more
Blood-Based Viral Signature Identified in Crohn’s Disease
Crohn’s disease is a chronic inflammatory intestinal disorder affecting approximately 0.4% of the European population, with symptoms and progression that vary widely. Although viral components of the microbiome... Read morePathology
view channel
World’s First Optical Microneedle Device to Enable Blood-Sampling-Free Clinical Testing
Blood sampling is one of the most common clinical procedures, but it can be difficult or uncomfortable for many patients, especially older adults or individuals with certain medical conditions.... Read more
Pathogen-Agnostic Testing Reveals Hidden Respiratory Threats in Negative Samples
Polymerase Chain Reaction (PCR) testing became widely recognized during the COVID-19 pandemic as a powerful method for detecting viruses such as SARS-CoV-2. PCR belongs to a group of diagnostic methods... Read moreTechnology
view channel
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more







